DEVELOPMENT OF A MONKEY MODEL FOR TESTING OF ANTIVIRAL AGENTS AGAINST HIV-1

开发用于测试 HIV-1 抗病毒药物的猴子模型

基本信息

  • 批准号:
    5200716
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

The development of an animal model system for infection and disease by HIV-1 is essential for AIDS vaccine studies and intervention. Currently, the only animal species which can be infected by HIV-1 is the chimpanzee; however, no disease is produced. Due to the enormous cost of maintaining a chimpanzee and the fact that this cannot be a disease model, a better model is sought. We have investigated infection, replication, persistence and clinical changes of HIV-1 in pig-tail macaques. In addition studies are underway to characterize a novel HIV-1/SIV chimeric virus, constructed in our laboratory, for its potential to replicate in pig-tail and rhesus monkeys. Four monkeys were inoculated with two isolates of HIV-1 which differ in their env regions: two monkeys designated as PT86 and PT99 received LAV, which is similar in its env to the laboratory adapted strain, HIV-1 IIIB; and two monkeys designated as PT87 and PT89 received a primary isolate (< 4 passages) which is similar in its env region to the MN strain, which represents the majority of North American HIV-1 isolates. Only PT86 and PT99 seroconverted. In case of PT86, an increasing antibody titer against all the HIV-1 proteins was seen by Western Blot analysis which has remained high at 68 weeks post inoculation (PI). Neutralizing antibodies developed at 6 weeks PI. From the early test time points, infectious HIV-1 was isolated from PBMCs at 4 weeks PI. PCR analysis of PBMCs indicated RNA expression at early time points (4, 6, 8 weeks PI) and again at 40 and 52 weeks PI. At 84 weeks PI, although PT86 has remained clinically healthy, a downward trend in CD4/CD8 may be occurring. In case of PT99, antibodies to only the env proteins were detected; however no virus has been isolated and the CD4/CD8 is stable. These results indicated that LAV infected and replicated in PT86 whereas no evidence of replication was seen in PT99. We have further analyzed the persistence of HIV-1 sequences in the inoculated monkeys. The results of DNA PCR using HIV-1 gag primers indicated that HIV-1 sequences were detected in the PBMCs of PT86 at all time points tested for up to about a year post-inoculation (last time confirmed) whereas the sequences in PT99 were consistently detected at early time points and then sporadically. In case of PT 87 and PT 89 HIV-1 sequences were detected reproducibly only at an early time point indicating infection of the animals but lack of replication. These results confirm that HIV-1 can infect but not replicate efficiently in monkeys. Furthermore, there are host factors that must be considered in selection of animals for development of an AIDS model.
感染和疾病的动物模型系统的开发, HIV-1对于艾滋病疫苗研究和干预至关重要。 目前, 唯一能被HIV-1感染的动物是黑猩猩; 但不会产生疾病。 由于维护成本巨大, 一只黑猩猩,事实上,这不可能是一个疾病模型, 模式是寻求。 我们研究了感染,复制, HIV-1在猪尾猕猴中的持久性和临床变化。在 另外的研究正在进行中,以表征一种新的HIV-1/SIV嵌合体 病毒,在我们的实验室构建,其复制的潜力, 猪尾猴和恒河猴。 四只猴子接种了两种HIV-1分离株, 它们的env区域:命名为PT86和PT99的两只猴子接受LAV, 其env与实验室适应株HIV-1 IIIB相似; 命名为PT87和PT89的两只猴子接受了初级分离株 (<4代),其env区域与MN菌株相似, 代表了大多数北美HIV-1分离株。 只有PT86和 PT99血清转化。 在PT86的情况下,增加的抗体滴度 免疫印迹分析显示, 在接种后68周(PI)仍然很高。 中和 在PI 6周产生抗体。 从早期的测试时间点来看, 感染性HIV-1在感染后4周从PBMC中分离。 pcr分析 PBMC在早期时间点(PI 4、6、8周)显示RNA表达 并在PI第40周和第52周再次进行。 在PI 84周时,尽管PT86具有 在临床上保持健康,CD4/CD8下降趋势可能是 正在发生。在PT99的情况下,仅针对env蛋白的抗体被检测到。 检测到;然而,没有分离出病毒,CD4/CD8是 稳定 这些结果表明,LAV感染和复制, PT86,而在PT99中没有观察到复制的证据。我们有 进一步分析了HIV-1序列在接种的 猴子用HIV-1 gag引物进行DNA PCR的结果表明, 在所有时间点,PT86的PBMC中均检测到HIV-1序列 接种后长达约一年的检测(最后一次确认) 而PT 99中的序列在早期就被一致地检测到 点,然后零星地。 如果是PT 87和PT 89 HIV-1序列 仅在早期时间点可重复检测到, 动物感染,但缺乏复制。这些结果证实 HIV-1可以感染猴子,但不能在猴子体内有效复制。 此外,在选择时必须考虑宿主因素 用于开发艾滋病模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

A S KHAN其他文献

A S KHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('A S KHAN', 18)}}的其他基金

STRUCTURAL AND FUNCTIONAL STUDIES OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源逆转录病毒序列的结构和功能研究
  • 批准号:
    3818206
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURAL AND FUNCTIONAL STUDIES OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源逆转录病毒序列的结构和功能研究
  • 批准号:
    3809632
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF A MONKEY MODEL FOR TESTING OF ANTIVIRAL AGENTS AGAINST HIV-1
开发用于测试 HIV-1 抗病毒药物的猴子模型
  • 批准号:
    3770322
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STUDY OF A MURINE RETROVIRUS FROM A PACKAGING CELL LINE USED IN GENE THERAPY
用于基因治疗的来自包装细胞系的鼠逆转录病毒的研究
  • 批准号:
    3770323
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURAL AND FUNCTIONAL ANALYSIS OF ENDOGENOUS PROVIRUSES OF MICE
小鼠内源原病毒的结构和功能分析
  • 批准号:
    3822045
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF A MONKEY MODEL FOR TESTING OF ANTIVIRAL AGENTS AGAINST HIV-1
开发用于测试 HIV-1 抗病毒药物的猴子模型
  • 批准号:
    3748151
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STUDY OF A MURINE RETROVIRUS FROM A PACKAGING CELL LINE USED IN GENE THERAPY
用于基因治疗的来自包装细胞系的鼠逆转录病毒的研究
  • 批准号:
    3748152
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
MOLECULAR ANALYSIS OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源性逆转录病毒序列的分子分析
  • 批准号:
    3792555
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURAL AND FUNCTIONAL STUDIES OF MAMMALIAN ENDOGENOUS RETROVIRAL SEQUENCES
哺乳动物内源逆转录病毒序列的结构和功能研究
  • 批准号:
    3790737
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
MOLECULAR BIOLOGY AND BIOCHEMICAL STRUCTRUE OF ENDOGENOUS PROVIRUSES OF MICE
小鼠内源性原病毒的分子生物学和生化结构
  • 批准号:
    4688492
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a
非人类灵长类艾滋病疫苗研究核心功能基因组学实验室
  • 批准号:
    8845051
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a
非人类灵长类艾滋病疫苗研究核心功能基因组学实验室
  • 批准号:
    8748807
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4
广泛保护性艾滋病疫苗的综合方法:项目 4
  • 批准号:
    8357598
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
New HIV/AIDS vaccines employing inflammatory dendritic cells
使用炎症树突状细胞的新型艾滋病毒/艾滋病疫苗
  • 批准号:
    8234958
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
New HIV/AIDS vaccines employing inflammatory dendritic cells
使用炎症树突状细胞的新型艾滋病毒/艾滋病疫苗
  • 批准号:
    8139488
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
OPTIMIZE THE IMMUNOGENICITY OF MVA-BASED AIDS VACCINES
优化基于 MVA 的艾滋病疫苗的免疫原性
  • 批准号:
    8357426
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4
广泛保护性艾滋病疫苗的综合方法:项目 4
  • 批准号:
    8172760
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: CORE B
广泛保护性艾滋病疫苗的综合方法:核心 B
  • 批准号:
    8172758
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Enhancing the Immunogenicity and Utility of MVA-Based AIDS Vaccines
增强基于 MVA 的艾滋病疫苗的免疫原性和实用性
  • 批准号:
    8075652
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
Enhancing the Immunogenicity and Utility of MVA-Based AIDS Vaccines
增强基于 MVA 的艾滋病疫苗的免疫原性和实用性
  • 批准号:
    7927768
  • 财政年份:
    2010
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了